COVID19
Hydrocortisone shown to improve recovery of critically ill COVID-19 patients: study
Sydney/Xinhua: A global study has shown anti-inflammatory drug hydrocortisone can improve the recovery of critically ill COVID-19 patients, adding to evidence which shows corticosteroids to be an effective tool in fighting the virus.
Led by researchers' from Australia's Monash University, the study which was released Thursday, involved patients from over 200 intensive care units worldwide.
In a randomised trial they found that those who received intravenous doses of hydrocortisone had a 93 percent probability of showing improved recovery and survival compared with those who received no corticosteroid.
The result adds to existing evidence from trials involving dexamethasone, another corticosteroid, proving that the specific class of anti-inflammatory can have a real difference in the fight against COVID-19.
"Our results suggest that the treatment effect of hydrocortisone is similar to that achieved with dexamethasone," study leader Professor Steve Webb from Monash University's School of Public Health and Preventive Medicine.
"The result will also help relieve pressure on supply of dexamethasone. This is not an additional treatment, but it is an alternative that is also effective."
The study was part of a larger initiative, called REMAP-CAP, established by a group of intensive care specialists from around the world to help deal with the more serious respiratory complications associated with COVID-19.
Support Our Journalism
We cannot do without you.. your contribution supports unbiased journalism
IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.
Support objective journalism for a small contribution.
